Aptorum Group

Aptorum Group FCF Conversion

Delisted·Sep 22, 2026

The FCF Conversion Rate (FCF/EBITDA) of Aptorum Group (APM) as of Oct 29, 2026 is 134.68 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 27.91 % — a change of 382.58% (higher).

FCF Conversion

134.68 %

YoY

382.58%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Aptorum Group is 2025 134.68 % . FCF Conversion Rate (FCF/EBITDA) of Aptorum Group was 2024 27.91 % . It decreases by 382.58% higher compared to the previous year.

The Aptorum Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
108.55 USD
Jan 1, 2019
77.54 USD
Jan 1, 2020
-227.72 USD
Jan 1, 2021
59.04 USD
Jan 1, 2022
127.61 USD
Jan 1, 2023
273.54 USD
Jan 1, 2024
27.91 USD
Jan 1, 2025
134.68 USD
The Aptorum Group FCF Conversion history
YEARFCF ConversionYoY
134.68 %+382.58%
27.91 %-89.80%
273.54 %+114.35%
127.61 %+116.13%
59.04 %-125.93%
-227.72 %-393.69%
77.54 %-28.57%
108.55 %-68.73%
347.16 %+52.90%
227.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptorum Group Stock analysis

What does Aptorum Group do? Aptorum Group Ltd. develops pharmaceutical products targeting unmet medical needs in infectious diseases, cancers, metabolic disorders, and neurology. The company leverages drug discovery platforms to screen approved drug molecules and microbiome-based research for metabolic treatments. It commercializes therapeutic assets through systematic screening and microbiome research, focusing on diseases like infectious conditions, cancer, and metabolic disorders. The company also pursues projects in gastroenterology, women’s health, and surgical robotics, alongside natural supplements for menopausal symptoms. Aptorum Group Ltd. generates revenue by advancing therapeutic and diagnostic projects across multiple disease areas. Its products include treatments for infectious diseases, cancers, and metabolic conditions, developed through drug discovery platforms and microbiome research. The company targets healthcare providers, pharmaceutical partners, and patients seeking innovative treatments for conditions with limited existing options. Segments include infectious disease therapies, cancer treatments, metabolic disorder solutions, and women’s health products. The company’s revenue streams come from the development and commercialization of therapeutic assets. It focuses on drug discovery through systematic screening of approved molecules and microbiome-based research for metabolic diseases. Projects in neurology, gastroenterology, and women’s health contribute to its product portfolio, alongside surgical robotics and natural supplements for menopausal symptoms. Aptorum Group Ltd. serves medical professionals and patients requiring novel treatments for underserved disease areas. Aptorum Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptorum Group stock

FCF Conversion Rate (FCF/EBITDA) of Aptorum Group is 134.68 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Aptorum Group changed from 27.91 % to 134.68 %, representing a 382.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Aptorum Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Aptorum Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Aptorum Group

All Key Metrics — Aptorum Group